NKGEN BIOTECH INC. -

NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

08 Oct 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial

12 Sep 2024 07:05:59 By Nasdaq GlobeNewswire

NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly Report

22 Aug 2024 15:40:47 By Nasdaq GlobeNewswire

NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference

30 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference

18 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors

15 Jul 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

12 Jun 2024 12:05:00 By Nasdaq GlobeNewswire

NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024

03 Jun 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 16:05:00 By Nasdaq GlobeNewswire

NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

20 May 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition

16 May 2024 07:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

25 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 Apr 2024 15:45:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit

18 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs

11 Apr 2024 07:05:02 By Nasdaq GlobeNewswire

NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference

25 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease

28 Dec 2023 15:05:14 By Nasdaq GlobeNewswire